

N-[5-(3-[2,6-Diamino-4(3H)-oxopyrimidin-5-yl]thio)-propyl)-3-methyl-thieno- 2-yl]-L-glutamic acid;

Q' N-[5-(3-[2,6-Diamino-4(3H)-oxopyrimidin-5-yl]thio)-propyl)-4-methyl-thieno- 2-yl]-L-glutamic acid;

N-(6-([2,6-diamino-4(3H)-oxopyrimidino-5-yl]thio)-methyl)-4,5,6,7-tetrahydrobenzothieno-2-yl)-S-glutamic acid;

N-(5-[2-([2,6-Diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]thieno-2-yl)-L-glutamic acid;

N-(4-[4-[2-([2,6-Diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]benzoyl)-L-glutamic acid; and the pharmaceutically acceptable salts thereof.

#### REMARKS

Reconsideration of the above application is respectfully requested.

Claims 52 and 54-61 are pending in the application. Claims 52 and 54-61 have been cancelled without prejudice. Claim 62 has been added. Entry of this amendment is requested. Upon entry of this amendment, claim 62 is pending.

##### I. Double Patenting Rejection

The Examiner has rejected claims 52 and 54-61 on the grounds of double patenting. Applicants respectfully traverse. Applicants respectfully submit that the Examiner's rejection is rendered moot by deletion of claims 52 and 54-61. Applicants, therefore, respectfully request that the Examiner remove his rejection on these grounds.

##### II. Claim Rejections Under 35 U.S.C. § 112, Second Paragraph

The Examiner has rejected claims 52 and 54-61 under 35 U.S.C. § 112, second paragraph, on the grounds of indefiniteness. Applicants respectfully traverse. Applicants respectfully submit that the Examiner's rejection is rendered moot by deletion of claims 52 and 54-61. Applicants, therefore, respectfully request that the Examiner remove his rejection on these grounds.